For Q1 FY2026 ended March 31, 2026, Fennec Pharmaceuticals reported revenue of $15.1M, up 72.6% year-over-year. Net income was $0.2M, compared to a net loss in the prior year, while operating loss narrowed to $0.1M. Diluted EPS was $0.01, up 125% YoY. The company held $40.2M in cash and $37.7M in equity, with long-term debt of $19.4M as of September 30, 2025.
•Revenue surged 72.6% YoY to $15.1M.
•Net income turned positive at $0.2M vs. a loss of $0.7M in Q1 FY2025.
•Operating loss improved 85.3% to $0.1M.
•Cash and equity stood at $40.2M and $37.7M, respectively.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Fennec Pharmaceuticals is a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment Norgine Pharma UK Limited.
Formerly known as Adherex Technologies Inc., the company rebranded as Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc. is a commercial stage biopharmaceutical company based in the United States. Its primary focus is on developing and commercializing therapies for patients with cancer. The company's lead product candidate is PEDMARK, a formulation of sodium thiosulfate designed to prevent cisplatin-induced ototoxicity (hearing loss) in pediatric patients. Cisplatin is a chemotherapy drug commonly used to treat various cancers, but it can cause permanent hearing damage, especially in children. PEDMARK aims to reduce this risk without compromising the anti-cancer efficacy of cisplatin. Fennec sells its products through regional pediatric oncology specialists and medical science liaisons, ensuring that healthcare providers are well-informed about the benefits and usage of PEDMARK.
On which stock exchange is Fennec Pharmaceuticals (FENC) listed and in what currency?
Fennec Pharmaceuticals Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol FENC. The company's shares are traded in US Dollars (USD), which is the official currency of the United States. Being listed on NasdaqCM provides Fennec with access to a broad base of investors and liquidity, as Nasdaq is one of the world's major stock exchanges. The choice of USD as the trading currency aligns with the company's operations being primarily based in the United States, where it generates revenue and incurs expenses.
What sector and industry does Fennec Pharmaceuticals (FENC) belong to?
Fennec Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Fennec focuses on using biological processes and living organisms to develop therapies for medical conditions. In particular, it is a commercial stage biopharmaceutical company, meaning it has advanced its product candidate to the market or is in the process of commercialization. The biotechnology industry is characterized by high research and development costs, long development cycles, and significant regulatory oversight. Fennec's specialization in oncology, specifically in preventing chemotherapy-induced side effects, places it at the intersection of cancer treatment and supportive care.
Where is Fennec Pharmaceuticals headquartered and what is its history?
Fennec Pharmaceuticals Inc. is headquartered in Research Triangle Park, North Carolina, United States. The company was originally incorporated in 1996 under the name Adherex Technologies Inc. In September 2014, the company rebranded to Fennec Pharmaceuticals Inc. to reflect its new strategic focus. The company has a collaboration with Tampa General Hospital Foundation, Inc. to evaluate the clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment. Additionally, Fennec has a partnership with Norgine Pharma UK Limited, indicating its efforts to expand its reach beyond the United States.
How does Fennec Pharmaceuticals (FENC) generate revenue?
Fennec Pharmaceuticals generates revenue primarily through the sale of its product PEDMARK, a formulation of sodium thiosulfate used to prevent cisplatin-induced ototoxicity in pediatric patients. The company sells its products through regional pediatric oncology specialists and medical science liaisons, who educate healthcare providers on the benefits of PEDMARK. As a commercial stage company, Fennec's revenue model is based on product sales, and it likely receives payments from hospitals, clinics, and other healthcare institutions. Additionally, the company may generate revenue through its collaborations, such as the one with Norgine Pharma UK Limited, which could involve licensing fees, milestone payments, or royalties. However, specific financial details are not provided in the available data.